Combination Immunotherapy Animation
This mechanism of action (MoA) animation was created for Bristol Myers Squibb (BMS) to visually convey the science behind their oncology combination treatment, OPDIVO® (nivolumab), and YERVOY® (ipilimumab). The drug combination is indicated for the treatment of advanced melanoma.
OPDIVO® + YERVOY® are two immunotherapies that BMS has combined to harness the body’s immune system to fight cancer. The animation tells the story of the combined medications and how they help the body attack cancer by shrinking tumors.
OPDIVO® is a monoclonal antibody, an anti-PD-1 drug, that promotes the tumor-killing effects of T-cells. YERVOY® is also a monoclonal antibody, an anti-CTLA-4 drug, that helps strengthen the immune system by promoting the function and growth of T-cells. The combination of these antibodies promotes an enhanced anti-tumor response.
This animation is hosted on the OPDIVO® HCP website for healthcare professionals (HCPs) to discover how these drugs work collectively.
Are you interested in seeing how our award-winning medical animation can help you?
Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.
‘‘For experts, there’s limited time in which they will interact with this content, so getting a message across quickly is crucial, and this medium does it very well.’’
Product Manager, GSK
‘‘Their turnaround time sets them apart from the rest of the field. The fact they can turnaround lots of comments in a couple of days is impressive, whereas that took weeks with other agencies we worked with. They’re well above the benchmark.’’
Oncology Clinical Liaison, Bristol-Myers Squibb
‘‘It was a combination equally of quality of work but also the comfort and confidence that I knew I would be working with PhDs. They gave me the confidence that they would have the ability to understand. The other companies didn’t have those sorts of people on staff, they were just good animators. That was the area where I felt that I could trust Random42 would deliver.’’
Senior Product Manager, Spectranetics
‘‘I have been to a lot of conferences and I have seen a lot of videos both from competitors and internally – in my eyes it is night and day. The quality Random42 have is not one step ahead, it is far ahead compared to what I have seen before.’’
Product Manager, Amgen